Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LFMD Stock Forecast 2025-2026
$15.06
Current Price
$684.44M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LFMD Price Targets
+19.5%
To High Target of $18.00
-10.4%
To Median Target of $13.50
-46.9%
To Low Target of $8.00
LFMD Price Momentum
+18.6%
1 Week Change
+42.3%
1 Month Change
+91.4%
1 Year Change
+204.2%
Year-to-Date Change
-1.5%
From 52W High of $15.29
+277.4%
From 52W Low of $3.99
📊 TOP ANALYST CALLS
Did LFMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LifeMD is one of their latest high-conviction picks.
Latest LFMD Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, LFMD has a bullish consensus with a median price target of $13.50 (ranging from $8.00 to $18.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $15.06, the median forecast implies a -10.4% downside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Sarah James at Cantor Fitzgerald, suggesting a 46.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFMD Analyst Ratings
6
Buy
1
Hold
0
Sell
LFMD Price Target Range
Low
$8.00
Average
$13.50
High
$18.00
Current: $15.06
Latest LFMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $14.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $14.00 |
| Mar 11, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
| Dec 10, 2024 | Lake Street | Buy | Initiates | $0.00 | |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $7.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Aug 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $15.00 |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $10.00 |
| Jun 5, 2024 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $12.00 |
| May 21, 2024 | B. Riley Securities | William Woods | Buy | Reiterates | $12.00 |
| May 10, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
| May 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $15.00 |
| Apr 23, 2024 | BTIG | David Larsen | Buy | Maintains | $14.00 |
| Mar 15, 2024 | BTIG | David Larsen | Buy | Maintains | $13.00 |
| Mar 12, 2024 | B. Riley Securities | William Woods | Buy | Reiterates | $12.00 |
| Mar 12, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $11.00 |
| Mar 12, 2024 | Craig-Hallum | Alex Fuhrman | Buy | Maintains | $15.00 |
LifeMD Inc. (LFMD) Competitors
The following stocks are similar to LifeMD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LifeMD Inc. (LFMD) Financial Data
LifeMD Inc. has a market capitalization of $684.44M with a P/E ratio of -28.4x. The company generates $234.01M in trailing twelve-month revenue with a -4.6% profit margin.
Revenue growth is +48.8% quarter-over-quarter, while maintaining an operating margin of +3.9% and return on equity of -2,243.1%.
Valuation Metrics
Market Cap
$684.44M
Enterprise Value
$609.82M
P/E Ratio
-28.4x
PEG Ratio
-376.5x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
+48.8%
Gross Margin
+86.8%
Operating Margin
+3.9%
Net Margin
-4.6%
EPS Growth
+48.8%
Financial Health
Cash/Price Ratio
+5.0%
Current Ratio
0.8x
Debt/Equity
-63.9x
ROE
-2,243.1%
ROA
-6.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
LifeMD Inc. (LFMD) Business Model
About LifeMD Inc.
What They Do
Provides direct-to-patient healthcare services.
Business Model
The company operates a direct-to-consumer model, generating revenue through telehealth consultations, prescription medications, and wellness products. By leveraging proprietary online platforms, LifeMD enhances the accessibility and affordability of healthcare services, tapping into the growing demand for virtual health solutions.
Additional Information
LifeMD addresses the limitations of traditional healthcare systems, focusing on underserved populations and contributing to the digital transformation in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
304
CEO
Mr. Justin Schreiber
Country
United States
IPO Year
2021
Website
lifemd.comLifeMD Inc. (LFMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Jun 12, 2025
By Debanjana Dey
Analyst Blog
Latest News
Quick Summary
LifeMD, Inc. (Nasdaq: LFMD) will participate in the BTIG Obesity Health Forum on June 18, 2025, with a virtual panel discussion on direct-to-consumer services.
Why It Matters
LifeMD's participation in investor conferences highlights its market engagement and growth strategy, potentially boosting investor confidence and interest in its stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
LifeMD: Growth, Growth, And More Growth
15 days ago
Quick Summary
LifeMD reports record Q1 revenue and first GAAP profit, driven by growth in GLP-1 programs and Medicare. Strong outlook despite high valuation; potential upside if growth continues.
Why It Matters
LifeMD's record revenue, first GAAP profit, and strong growth drivers signal a solid investment opportunity, despite high earnings valuation, suggesting potential for significant upside.
Source: Seeking Alpha
Market Sentiment:
Positive
Top 2 Health Care Stocks That May Implode In Q2
27 days ago
Quick Summary
As of May 23, 2025, two health care stocks may signal caution for momentum-focused investors.
Why It Matters
Momentum in health care stocks may be weakening, signaling potential declines, which could lead to increased volatility and risk for investors focused on growth strategies.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
LifeMD offers a bundled weight loss program including Wegovy® for $299 in the first month and $599 monthly thereafter.
Why It Matters
The bundled offer indicates a strategic pricing move by LifeMD, potentially increasing customer acquisition and revenue, impacting its stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LifeMD, Inc. (Nasdaq: LFMD) will participate in several investor conferences in May 2025, highlighting its position in virtual primary care services.
Why It Matters
LifeMD's participation in investor conferences signals active engagement with the investment community, potentially enhancing visibility and investor confidence, influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LifeMD, Inc. reported Q1 2025 revenues of $65.7 million, up 49% YoY, with telehealth revenue increasing 70%. Adjusted EBITDA rose to $8.7 million, and GAAP net income was $0.6 million. Full-year guidance raised.
Why It Matters
Strong revenue growth and first-ever positive GAAP EPS signal robust business performance, particularly in telehealth. Increased guidance suggests continued momentum, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LFMD Stock
What is LifeMD Inc.'s (LFMD) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, LifeMD Inc. (LFMD) has a median price target of $13.50. The highest price target is $18.00 and the lowest is $8.00.
Is LFMD stock a good investment in 2025?
According to current analyst ratings, LFMD has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LFMD stock?
Wall Street analysts predict LFMD stock could reach $13.50 in the next 12 months. This represents a -10.4% decrease from the current price of $15.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LifeMD Inc.'s business model?
The company operates a direct-to-consumer model, generating revenue through telehealth consultations, prescription medications, and wellness products. By leveraging proprietary online platforms, LifeMD enhances the accessibility and affordability of healthcare services, tapping into the growing demand for virtual health solutions.
What is the highest forecasted price for LFMD LifeMD Inc.?
The highest price target for LFMD is $18.00 from at , which represents a 19.5% increase from the current price of $15.06.
What is the lowest forecasted price for LFMD LifeMD Inc.?
The lowest price target for LFMD is $8.00 from Sarah James at Cantor Fitzgerald, which represents a -46.9% decrease from the current price of $15.06.
What is the overall LFMD consensus from analysts for LifeMD Inc.?
The overall analyst consensus for LFMD is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are LFMD stock price projections?
Stock price projections, including those for LifeMD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 6:41 AM UTC